High Cholesterol & Dyslipidaemia:
Causes, Risk & Modern Treatment

At a glance

FrequencyElevated LDL cholesterol affects a large proportion of adults — many are unaware
Why it mattersElevated LDL cholesterol is one of the most important risk factors for heart attack and stroke
Key markerLDL cholesterol (Low-Density Lipoprotein) — the lower, the better for cardiovascular risk
TreatmentLifestyle changes + statins as first-line therapy, plus ezetimibe, bempedoic acid, PCSK9 inhibitors when needed
GuidelineESC/EAS 2025 Focused Update on Dyslipidaemia
ICD-10E78 (Disorders of lipoprotein metabolism)

1. What is high cholesterol?

Cholesterol is a vital component of every body cell. The body produces most of it itself, with some taken in via food. The problem arises when LDL cholesterol (colloquially: "bad cholesterol") is persistently elevated — because LDL accumulates in blood vessel walls and promotes atherosclerosis.¹

Elevated LDL cholesterol is one of the most important modifiable risk factors for heart attack, stroke and other cardiovascular diseases. The evidence is clear: the lower the LDL cholesterol, the lower the risk — the ESC/EAS guideline (Focused Update 2025) frames this as a fundamental principle.¹

Well treatable — even without symptoms High cholesterol is generally well treatable — through a combination of lifestyle changes and medications. As the condition causes no symptoms for a long time, regular checks are particularly important.

2. LDL, HDL, triglycerides — what do the values mean?

  • LDL cholesterol: Carries cholesterol into blood vessels and deposits it there. Elevated values promote atherosclerosis. The most important treatment target.¹
  • HDL cholesterol: Transports excess cholesterol back to the liver (protective function). Low values are considered a risk factor. However, currently no medication has been shown to reduce cardiovascular risk by raising HDL.
  • Triglycerides: Blood fats that rise with excess energy intake (especially sugar, alcohol, overweight). Significantly elevated triglycerides can increase cardiovascular risk and, in rare cases, trigger acute pancreatitis.
  • Total cholesterol: The sum of LDL, HDL and VLDL. Often measured but less informative than LDL cholesterol alone.
  • Lipoprotein(a) (Lp(a)): A genetically determined risk factor included as a risk modifier in the ESC/EAS Update 2025. Should typically be measured once in a lifetime. Currently cannot be effectively treated with medication — new therapies are in development.

3. Causes and risk factors

  • Diet: A high proportion of saturated fats (fatty meat, sausage, cheese, butter, coconut oil) and trans fats (fried foods, baked goods, processed products) can raise LDL.
  • Lack of exercise: sedentary lifestyle.
  • Overweight: obesity typically raises LDL and triglycerides and lowers HDL.
  • Genetics: Familial hypercholesterolaemia (FH) is a common genetic condition leading to markedly elevated LDL from a young age. It is often unrecognised (see separate section below).
  • Other conditions: hypothyroidism, chronic kidney disease, type 2 diabetes, liver disease.
  • Medications: Certain medications can affect lipid metabolism (e.g. corticosteroids, beta-blockers, thiazide diuretics, immunosuppressants).

4. Symptoms

High cholesterol typically causes no symptoms This is why it is often only detected once cardiovascular disease has occurred (heart attack, stroke, peripheral arterial disease). Regular blood tests are therefore important — particularly if there are risk factors or a positive family history.¹

With very markedly elevated values (especially in familial hypercholesterolaemia), visible signs can appear:

  • Xanthomas: cholesterol deposits in tendons or under the skin
  • Xanthelasmas: yellowish deposits on the eyelids
  • Arcus lipoides: a whitish ring around the cornea

These signs are rare but diagnostically pointing — they should raise suspicion of a familial form.


5. Diagnosis and risk assessment

  • Lipid profile: total cholesterol, LDL, HDL, triglycerides — typically fasting or non-fasting (results are comparable for most values). LDL is the decisive target.
  • Risk assessment: The ESC/EAS guideline recommends individual risk assessment — in the 2025 update with SCORE2 (for ages 40–69) and SCORE2-OP (for ages 70–89). Total risk determines LDL targets and treatment intensity.¹
  • LDL targets (ESC/EAS 2025): Depend on individual cardiovascular risk. The higher the risk, the lower the target. For people with established cardiovascular disease or very high risk, the lowest targets typically apply.¹
  • Lipoprotein(a): Recommended in the 2025 Update as a risk modifier — should typically be measured once in a lifetime.

6. Treatment: lifestyle

Lifestyle changes are the foundation of every cholesterol therapy — regardless of whether medications are used.¹

  • Reduce saturated fats — less fatty meat, sausage, cheese, butter, coconut oil; instead choose unsaturated fats (olive oil, nuts, avocado, oily fish)
  • Avoid trans fats — fried foods, industrial baked goods, processed products
  • Increase fibre — wholegrains, vegetables, pulses, fruit
  • Normalise weight if overweight
  • Regular exercise — can lower LDL and raise HDL
  • Stop smoking — smoking damages blood vessels independently of cholesterol
  • Reduce alcohol — can lower triglycerides

7. Treatment: medications

When lifestyle changes alone are not enough to reach individual LDL targets, medications are used. The decision is based on overall risk.¹

First line Statins

Statins are the most thoroughly studied and most widely used cholesterol-lowering medications. They inhibit the body's own cholesterol production in the liver and can substantially lower LDL cholesterol. Statins have been shown to reduce the risk of heart attack, stroke and cardiovascular death.¹

  • Typically taken once daily (usually in the evening)
  • Common side effects: muscle complaints (mostly mild and transient); rarely severe muscle damage
  • Liver enzymes can rise mildly — typically checked at the start
  • Many people tolerate statins well — a relevant proportion of reported intolerances are not caused by the medication, according to studies (nocebo effect)
Combination Ezetimibe
Ezetimibe
Inhibits cholesterol absorption in the intestine. Often combined with statins when a statin alone is insufficient. Can also be used as monotherapy when statins are not tolerated.
New 2025 Bempedoic acid
Bempedoic acid
New in the ESC/EAS 2025 guidelines. An oral medication that, like statins, inhibits cholesterol production but with a different mechanism of action. Recommended for statin intolerance or as an add-on to statins.¹
Escalation PCSK9 inhibitors
Evolocumab, alirocumab
Highly effective LDL-lowering medications administered as an injection. Typically used when statins + ezetimibe + bempedoic acid are insufficient or not tolerated. Reimbursement is tied to specific criteria.
Triglycerides Fibrates
Fibrates
Used for significantly elevated triglycerides.
Statins: benefit typically clearly outweighs the risks Statins are among the most thoroughly studied medications in existence. For people at elevated cardiovascular risk, the benefit typically clearly outweighs the risks. Statins should not be stopped on your own — for suspected side effects, speak to your treating practice.

8. Familial hypercholesterolaemia

Familial hypercholesterolaemia (FH) is a common genetic condition that leads to markedly elevated LDL values — already from a young age and independent of lifestyle. The heterozygous form affects approximately one in several hundred people by current estimates, but is typically substantially underdiagnosed.¹

  • Suspect with markedly elevated LDL (particularly at a younger age), positive family history (heart attack or stroke in relatives before age 55 (men) or 60 (women)), xanthomas
  • Diagnosis: clinical scoring systems (e.g. Dutch Lipid Clinic Network Score) and/or genetic testing
  • Treatment: early and consistent LDL lowering (statins + ezetimibe, plus PCSK9 inhibitors when needed); lifestyle changes alone are typically insufficient for FH
  • Cascade screening: first-degree relatives should also be tested

How brite helps you with high cholesterol

Statin in the evening, ezetimibe alongside, a new LDL result every three months and the question of whether the target has been reached — and in the background blood pressure and diabetes too. Cholesterol therapy is often part of a bigger cardiovascular plan. brite keeps it organised.

  • Intake reminder — statin in the evening, ezetimibe or bempedoic acid in the morning: brite reminds you on time. Particularly because statins are taken for life, routine helps.
  • Drug interaction check — statin plus grapefruit juice? Plus macrolide antibiotics? Plus certain antifungals? brite shows when statin levels can rise unintentionally — and with them the risk of muscle side effects.
  • Health journal — track LDL, HDL, triglycerides and total cholesterol over time. So you can see clearly whether therapy is reaching the LDL target — or whether escalation might make sense.
  • Digital medication plan — all medications clearly organised for cardiology, GP and lipid clinic. Particularly helpful when blood pressure medications and antidiabetics come into the picture too.
Start free now
brite App

FAQ: Common questions about high cholesterol

LDL cholesterol. It is the central treatment target and the most important modifiable risk factor for heart attack and stroke. The target value depends on individual cardiovascular risk.¹
Generally yes — when there is a clear indication (elevated cardiovascular risk or established cardiovascular disease). Cholesterol typically rises again after stopping, and the protective effect is lost. Statins should not be stopped on your own.
Muscle symptoms are the most commonly reported side effect but are usually mild and often transient. Studies show that a relevant proportion of muscle complaints with statins are not caused by the medication (nocebo effect). For suspected side effects, speak to your treating practice — often there are alternatives.
A new oral cholesterol-lowering medication that was added to the ESC/EAS guidelines in 2025. It inhibits cholesterol production via a different mechanism than statins. Recommended for statin intolerance or as an add-on when LDL targets are not reached.¹
A common genetic condition with markedly elevated LDL from a young age. It is often unrecognised. Affected individuals have a significantly higher risk of early heart attacks. Early diagnosis and consistent treatment are crucial. First-degree relatives should also be tested.¹
Lifestyle changes (diet, exercise, weight) can typically lower LDL moderately. For higher risk or significantly elevated values, lifestyle alone is usually insufficient — medications (especially statins) are then recommended. For familial hypercholesterolaemia, diet alone is not enough.
For most clinical decisions, a non-fasting lipid profile is sufficient. Fasting values can be more accurate in cases of significantly elevated triglycerides. The treating practice will typically advise.
A genetically determined risk factor for cardiovascular disease, included as a risk modifier in the ESC/EAS Update 2025. It should typically be measured once in a lifetime. It currently cannot be effectively treated with medication — new therapies are in development.¹

Sources

  1. ESC/EAS 2025 Focused Update of the Dyslipidaemia Guidelines (building on the 2019 guideline). eurheartj (Oxford Academic)
  2. NICE Guideline NG181: Cardiovascular disease — risk assessment and reduction, including lipid modification. nice.org.uk
  3. HEART UK — The Cholesterol Charity. heartuk.org.uk
  4. NHS: High cholesterol. nhs.uk
Medical disclaimer: This article is for general information only and does not replace medical advice, diagnosis or treatment. LDL targets and treatment intensity depend on individual cardiovascular risk and are determined by the treating practice. Statins and other lipid-lowering medications should not be stopped on your own. Last updated: April 2026.